Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02964988
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Overview
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sponsor
Rigshospitalet
Phase
Phase 2
Contacts
Marie Fosboel, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT02964988Drug / Compound
NOTA-AE105
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- uPAR
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA
Radium-223 dichloride
Isotope(s):
RADIUM-223
Radioisotope: Ra-223
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 11.4 Days
Decay Mode: ALPHA, BETA, GAMMA
Energy: Alpha (95%) 5-7.5 MeV Beta (3.6%) 445-492 keV Gamma (1%) 82-402 keV
Range: In Tissue <100 micrometers
Decay Daughters: 4 alpha daughters: Rn219, Po211,215, Bi211
Status: FDA Approval: XOFIGO® (2013)
Target(s):
- No Explicit Target
Eligibility
Inclusion
- Approved to receive Radium-223 therapy
- * Metastatic castration resistant prostate cancer
- Written and oral consent
Exclusion
- * Lack of communication skills
- Severe claustrophobia
- If a participant exhibits allergic reaction i the IMP, the participant will be excluded from further participation in the study
- Other known malignant disease
- Known allergy towards IMP
Share your feedback
Help us improve your experience